ARTICLE | Company News
Astute, bioMerieux deal
February 2, 2015 8:00 AM UTC
Astute granted bioMerieux semi-exclusive, worldwide rights to develop and commercialize Astute’s NephroCheck test for early risk assessment of acute kidney injury on bioMerieux’s Vidas diagnostic pla...